New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
08:56 EDTBAXBaxter: Guidance contemplates possible headwinds related to cyclo competition
Says positive momentum continues to build, off to a strong start for the year. Says well positioned for sustained performance. Says global demand for Advate remains very strong. Says demand for Feiba remains robust. Says to date, has not experienced any new competition for cyclophosphamide. Says wide guidance range contemplates potential headwinds related to cyclophosphamide competition, foreign currency. Says guidance currently assumes FY cyclo benefit 20c per share. Sees FY interest expense $160M. Sees FY tax rate 21.5%. Says U.S. growth may moderate, but sees international growth accelerating on sequential basis in Q3, Q4. Sees FY CapEx approx. $1.8B. Sees FY Medical Products sales up 1%-2% excluding GAMBRO. Sees competition for cyclo later this year. Sees Specialty Pharmaceuticals sales growth in the 3%-5% range. Sees BioTherapeutics sales up 4%, BioSurgery/Vaccines sales growth in the low single digits. Comments made on the Q2 earnings conference call.
News For BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
09:05 EDTBAXBaxter files for European approval of investigational IGSC 20% treatment for PI
Baxter International announced that its BioScience business has submitted a marketing authorization application to 17 competent authorities in Europe following the decentralized procedure for approval of its investigational 20% concentration subcutaneous immune globulin, or IGSC, treatment for primary immunodeficiencies, or PI, a group of disorders in which part of the body's immune system is missing or does not function properly. Results from a separate study of IGSC 20% among patients with PI in North America are expected to be available in the coming months; based on the outcome of this study, Baxter intends to file for U.S. approval of the treatment before the end of 2015.
06:38 EDTBAXNovo Nordisk rejects claims made by Baxter, Reuters says
Novo Nordisk (NVO) rejects claims made by Baxter (BAX) that the company used substances made by Baxter in its Novoeight haemophilia treatment, following Monday's ITC investigation announcement, reports Reuters, citing an email from Novo Nordisk. Reference Link
May 18, 2015
12:24 EDTBAXBaxter sees FY16 sales growth 2%-3%
Subscribe for More Information
12:20 EDTBAXBaxter sees 2H sales growth approximately flat in constant currency
Subscribe for More Information
08:39 EDTBAXBaxter says Baxalta separation on-track for mid-year 2015
Subscribe for More Information
May 15, 2015
17:31 EDTBAXBaxter gets FDA approval for Spain facility to produce Sodium Chloride Injection
Subscribe for More Information
May 13, 2015
10:40 EDTBAXBaxter to host two day investor meeting
Two day Investor meeting to be held in New York May 18-19.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use